Cart
Orders
Not available here
Product Overview
Wegovy 0.25mg contains Semaglutide and is a prescription medicine presented as a solution for injection. The grouped strengths are 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg. Packaged contents differ between US single-dose pens and UK FlexTouch pens; the strength in the product name does not always represent the total Semaglutide content of a pen.
Composition & Specifications
| Property | Wegovy 0.25mg |
|---|---|
| Main ingredient | Semaglutide |
| Product category | Prescription medicine |
| Dosage form | Solution for injection |
| US single-dose pen contents | 0.25 mg/0.5 mL per pen |
| UK FlexTouch pen contents | 1.0 mg in 1.5 mL per pen |
Strengths & Packaged Presentations
All five strengths contain Semaglutide. The table compares total labeled contents per pen for the specified market presentations, not treatment amounts.
| Product | US single-dose pen | UK FlexTouch pen |
|---|---|---|
| Wegovy 0.25mg | 0.25 mg/0.5 mL | 1.0 mg in 1.5 mL |
| Wegovy 0.5mg | 0.5 mg/0.5 mL | 2.0 mg in 1.5 mL or 2.0 mg in 3 mL, depending on presentation |
| Wegovy 1.0mg | 1 mg/0.5 mL | 4.0 mg in 3 mL |
| Wegovy 1.7mg | 1.7 mg/0.75 mL | 6.8 mg in 3 mL |
| Wegovy 2.4mg | 2.4 mg/0.75 mL | 9.6 mg in 3 mL |
For these strengths, US single-dose pen cartons contain 4 pens. UK FlexTouch packs contain 1 pre-filled pen and 4 disposable NovoFine Plus needles. A separate US Wegovy 2.4mg FlexTouch presentation contains 9.6 mg/3 mL (3.2 mg/mL), packaged as 1 pen and 4 NovoFine Plus needles.
Product Label & Regulatory Notes
The UK leaflet identifies Novo Nordisk A/S as the marketing authorisation holder and lists Novo Nordisk A/S and Novo Nordisk Production SAS as manufacturers. The US and UK presentations described here have different package configurations. Their market-specific label information does not establish authorisation in other jurisdictions.